Pieranna Chiarella*, Pasquale Capone and Renata Sisto

Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, Italian Workers’ Compensation Authority - INAIL, Monte Porzio Catone, Rome, Italy

*Corresponding Author: Pieranna Chiarella, Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, Italian Workers’ Compensation Authority - INAIL, Monte Porzio Catone, Rome, Italy.

Received: May 26, 2023; Published: June 10, 2023

Abstract

In 2015, the European Food and Safety Authority (EFSA) evaluated the worldwide consumption of coffee to verify the potential use and abuse of caffeine by the population, with the aim to identify potential adverse effects on the human health. The conclusion of the survey was the following: single doses of caffeine up to 200/400 mg did not give rise to safety concerns.

Methods: Caffeine is one of the most widely consumed substance and beverage in the world, showing not only benefits, as excellent source of antioxidants, but also offering to prevent inflammatory and oxidative stress-related diseases, including obesity, metabolic syndrome and type 2 diabetes. In the elderly people with several comorbidities, caffeine contributed to reduce several neurological disorders, such as senile dementia, Alzheimer’s and Parkinson’s disease, contributing to alleviate tremors and helping the memory loss in elderly subjects.

Results: It is widely known CYP1A2 polymorphic enzyme (AA) (AC) (CC) is responsible for different levels in the caffeine metabolism, leading to a distinction in separate categories where CYP1A2*1A allele (AA) are "rapid" caffeine metabolizers, in contrast to carriers of the variant CYP1A2*1F who are "slow" caffeine metabolizers (AC-CC). In the absence of biological matrix, such as blood and urine, we performed in silico analysis of the genetic polymorphism CYP1A2*1A rs762551 distributed into five different ethnic groups of 210 subjects, including Caucasian, Africans, Americans, South Asians and East Asians.

Conclusions: The goal of this study is to identify potential significant difference in metabolism of caffeine to verify the most susceptible individuals in five ethnic groups.

Keywords:Caffeine; Metabolism; CYP1A2; Polymorphic Gene; Slow and Fast Metabolizers Caffeine; Metabolism; CYP1A2; Polymorphic Gene; Slow and Fast Metabolizers

References

1. Barrea , et al. “Coffee consumption, health benefits and side effects: a narrative review and update for dietitians and nutritionists”. Critical Reviews in Food Science and Nutrion 63.9 (2023): 1238-1261.
2. Caldwell JA., et al. “Caffeine intake and its sources: A survey instrument to assess intake of dietary supplements, related products, and caffeine in high-use populations”. The Journal of Nutrition2 (2018): 1445S-1451S.
3. Cappelletti S., et al. “A systematic review of caffeine-related suicides and an analysis of the controversial role of caffeine consumption in suicidal risk”. Rivista di Psichiatria6 (2021): 283-288.
4. Centers for Disease Control and Prevention. “Alcohol and caffeine dangers of mixing alcohol with caffeine and energy drinks” (2022).
5. Chiarella P., et al. “A predictive model assessing genetic susceptibility risk at workplace”. 2019. International Journal of Environmental Research and Public Health11 (2022): 2012.
6. Cornelis MC., et al. “Genetic polymorphism of the adenosine A_2A receptor is associated with habitual caffeine consumption”. The American Journal of Clinical Nutrition1 (2007): 240-244.
7. Cornelis MC., et al. “Coffee, CYP1A2 genotype, and risk of myocardial infarction”. JAMA10 (2006): 1135-1141.
8. Ensembl GRch37 (2023).
9. Eskelinen MH and Kivipelto M. “Caffeine as a protective factor in dementia and Alzheimer's disease”. Journal of Alzheimer’s Disease1 (2010): S167-174.
10. European Food Safety Authority. NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies). 2015. “Scientific Opinion on the safety of caffeine”. EFSA Journal5 (2015): 4102-4120.
11. Fredholm BB., et al. “Actions of caffeine in the brain with special reference to factors that contribute to its widespread use”. Pharmacological Reviews1 (1999): 83-133.
12. Gleason JL., et al. “Association of maternal caffeine consumption during pregnancy with child growth”. JAMA Network Open10 (2022): e2239609.
13. Gongora-Alfaro JL. “Caffeine as a preventive drug for Parkinson’s disease: epidemiologic evidence and experimental support”. Revista de Neurologia 4 (2010): 221-229.
14. Gu L., et al. “Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA expressed human CYP1A2 and CYP2E1”. Pharmacogenetics 2 (1992): 73-77.
15. Herforth A., et al. “Methods and options to monitor the cost and affordability of a healthy diet globally”. Background paper for The State of Food Security and Nutrition in the World 2022. FAO Agricultural Development Economics Working Paper 22-03. Rome, FAO (2022).
16. International Institute for Sustainable Development. Bermudez, S., Voora V., and Larrea, C. “Global Market Report: Coffee prices and sustainability” (2022).
17. Je Y., et al. “A Prospective cohort study of coffee consumption and risk of endometrial cancer over a 26-year of follow-up”. Cancer Epidemiology Biomarkers and Prevention12 (2011): 2487-2495.
18. Lafranconi A., et al. “Coffee Intake decreases risk of postmenopausal breast cancer: A dose-response meta-Analysis on prospective cohort studies”. Nutrients2 (2018): 112.
19. Nawrot P., et al. “Effects of caffeine on human health”. Food Additives and Contaminants 1 (2003): 1-30.
20. Nehlig A. “Effects of coffee/caffeine on brain health and disease: what should I tell my patients?” Practical Neurology2 (2016): 89-95.
21. Nehlig A and Debry G. “Potential genotoxic, mutagenic and antimutagenic effects of coffee: a review”. Mutation Research2 (1994): 145-162.
22. Palatini P., et al. “CYP₁A₂ genotype modifies the association between coffee intake and the risk of hypertension”. Journal of Hypertension8 (2009): 1594-1601.
23. Qian J., et al. “Impacts of caffeine during pregnancy. Trends Endocrinology and Metabolism3 (2020): 218-227.
24. Ren X and Chen JF. “Caffeine and Parkinson's disease: multiple benefits and emerging mechanisms”. Frontiers in Neuroscience 14 (2020): 602697.
25. Ruggiero M., et al. “Neurodegenerative diseases: can caffeine be a powerful ally to weaken neuroinflammation?” International Journal of Molecular Sciences21 (2022): 12958.
26. Sachse C., et al. “Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine”. British Journal of Clinical Pharmacology4 (1999): 445-449.
27. Schubert MM., et al. “Caffeine, coffee, and appetite control: a review”. International Journal of Food Sciences and Nutrition8 (2017): 901-912.
28. Torres-Collado L., et al. “Coffee consumption and all-cause, cardiovascular, and cancer mortality in an adult mediterranean population”. Nutrients4 (2021): 1241.
29. Turnbull D., et al. “Caffeine and cardiovascular health”. Regulatory Toxicology and Pharmacology 89 (2017): 165-185.
30. Verster JC and Koenig J. “Caffeine intake and its sources: A review of national representative studies”. Critical Reviews in Food Science and Nutrition8 (2018): 1250-1259.
31. Walter K. “Caffein and health”. JAMA 7 (2022): 693.
32. Westra AE and de Beaufort I. “Improving the Helsinki declaration's guidance on research in incompetent subjects”. Journal of Medical Ethics3 (2020): 278-280.
33. Wierzejska R. “Caffeine-common ingredient in a diet and its influence on human health”. Rocz Roczniki Państwowego Zakładu Higieny 2 (2012): 141-147.
34. Wierzejska R. “Coffee consumption and cardiovascular diseases - has the time come to change dietary advice? A mini review”. Polish Journal of Food and Nutrition Sciences 66.1 (2016): 5-10.
35. Anna Eva Westra. “Ambiguous articles in new EU regulation may lead exploitation of vulnerablie research subjects”. Journal of Medical Ethics 42 (2016): 189-191.

Citation

Citation: Pieranna Chiarella.,et al. “Variability of Caffeine Metabolism by CYP1A2 Polymorphism in Different Populations".Acta Scientific Nutritional Health 7.7 (2023): 43-50.

Copyright

Copyright: © 2023 Pieranna Chiarella., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.